Stockscreener 앱 받기
2.02
8.58%
-0.20
전일 마감가:
$2.22
열려 있는:
$2.23
하루 거래량:
706.79K
Relative Volume:
0.71
시가총액:
$260.65M
수익:
$36.86M
순이익/손실:
$-171.67M
주가수익비율:
-0.9902
EPS:
-2.04
순현금흐름:
$-171.05M
1주 성능:
-19.46%
1개월 성능:
-3.36%
6개월 성능:
-22.54%
1년 성능:
+28.45%
1일 변동 폭
$2.015
$2.29
1주일 범위
$1.98
$2.61
52주 변동 폭
$1.22
$6.2801
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MRSN | 2.02 | 260.65M | 36.86M | -171.67M | -171.05M | -2.04 |
| VRTX | 450.57 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.41 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.84 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
This Particular Biotech Stock Is Soaring On Two Key Announcements - MSN
Mersana Therapeutics (STU:0M4) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Mersana Therapeutics Q3 2024 Earnings Preview - MSN
16,178 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Acquired by US Bancorp DE - Defense World
Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World
Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World
Wedbush Expects Increased Earnings for Mersana Therapeutics - MarketBeat
FY2024 Earnings Estimate for MRSN Issued By Leerink Partnrs - MarketBeat
Mersana Therapeutics transferred with Buy rating at Citi - MSN
MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com
Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com
Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated at Citigroup - MarketBeat
MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com
Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World
MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Free Cash Flow : $-95.57 Mil (TTM As of Sep. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.63 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com
MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com
MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com
Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials - Investing.com India
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey
Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India
Earnings call: Mersana Therapeutics reports progress in ADC clinical trials By Investing.com - Investing.com UK
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
FANG Index (FGU25) Quote - The Globe and Mail
Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates - MarketWatch
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Mersana Therapeutics (MRSN) Q3 2024 Earnings: EPS Loss of $0.09 Beats Estimates, Revenue Surges to $12.6M - GuruFocus.com
Mersana Therapeutics Reports Progress in Cancer Treatments - TipRanks
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewswire
Mersana Therapeutics, Inc. Provides Business Update - Marketscreener.com
Earnings Preview For Mersana Therapeutics - Benzinga
Mersana Therapeutics presents new data on XMT-2056 - BioWorld Online
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Price Target from Brokerages - Defense World
Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly? - Simply Wall St
Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00 - MarketBeat
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):